Literature DB >> 17350145

Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection.

Matthew J Sylte1, Bolyn Hubby, David L Suarez.   

Abstract

Protection of chickens against avian influenza (AI) is mostly attributed to production of antibodies against the viral glycoprotein hemagglutinin, whereas less is known about the protective role of antibodies to the other surface glycoprotein neuraminidase (NA). Therefore, vaccines encoding NA antigen (e.g., DNA and alphavirus-based virus like replicon particles (VRP)) or baculovirus-expressed recombinant NA (rN2) were tested for their ability to protect against highly pathogenic AI (HPAI) in chickens. Vaccination with A/Pheasant/Maryland/4457/93 (Ph/MD) rN2 protein produced significantly higher levels of NA-inhibition (NI) activity and 88% protection from HPAI H5N2 challenge than vaccination with Ph/MD N2 DNA (25% protection). Vaccination with Ph/MD N2 VRP a minimum of two times also produced high levels of NI activity and protection against HPAI challenge (63% protection). Vaccination with VRP encoding an N2 gene that was genetically distant from the challenge virus N2 failed to protect chickens. Vaccines producing higher levels of NI activity conferred partial protection, but failed to affect viral shedding. Consideration of the homology between vaccine and challenge virus isolate NA genes may provide improved immunity if high levels of NI activity are obtained.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17350145     DOI: 10.1016/j.vaccine.2007.02.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

1.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

Review 2.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

3.  Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.

Authors:  Gale E Smith; Xiangjie Sun; Yaohui Bai; Ye V Liu; Michael J Massare; Melissa B Pearce; Jessica A Belser; Taronna R Maines; Hannah M Creager; Gregory M Glenn; David Flyer; Peter Pushko; Min Z Levine; Terrence M Tumpey
Journal:  Virology       Date:  2017-06-16       Impact factor: 3.616

4.  Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.

Authors:  Lisa Walz; Sarah-Katharina Kays; Gert Zimmer; Veronika von Messling
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

5.  Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses.

Authors:  Ahmed Kandeil; Yassmin Moatasim; Mokhtar R Gomaa; Mahmoud M Shehata; Rabeh El-Shesheny; Ahmed Barakat; Richard J Webby; Mohamed A Ali; Ghazi Kayali
Journal:  Vaccine       Date:  2015-11-25       Impact factor: 3.641

6.  Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.

Authors:  Fu-Shi Quan; Min-Chul Kim; Byeong-Jae Lee; Jae-Min Song; Richard W Compans; Sang-Moo Kang
Journal:  Virology       Date:  2012-06-02       Impact factor: 3.616

7.  Development of neuraminidase subtype-specific reference antisera by recombinant protein expressed in baculovirus.

Authors:  Kyu-Jun Lee; Jun-Gu Choi; Hyun-Mi Kang; Kwang-Il Kim; Choi-Kyu Park; Youn-Jeong Lee
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

8.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

9.  Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.

Authors:  Joshua M DiNapoli; Baibaswata Nayak; Lijuan Yang; Brad W Finneyfrock; Anthony Cook; Hanne Andersen; Fernando Torres-Velez; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

Review 10.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.